Suppr超能文献

异基因造血细胞移植后反复血流感染。

Recurrent bloodstream infections after allogeneic hematopoietic cell transplantation.

机构信息

Department of Bone Marrow Transplantation, National Research Center for Hematology, Moscow, Russia.

Laboratory of Microbiology, Mycology and Antibacterial Therapy, National Research Center for Hematology, Moscow, Russia.

出版信息

Expert Rev Anti Infect Ther. 2023 Jan;21(1):87-90. doi: 10.1080/14787210.2023.2151440. Epub 2022 Nov 28.

Abstract

BACKGROUND

Although colonization is an established risk factor for bloodstream infection (BSI) due to identical strain, prior infection with resistant bacteria should also be considered during the management of febrile neutropenia. This study aimed to analyze the rate and etiology of recurrent BSI in allogeneic hematopoietic cell transplant (allo-HCT) recipients to determine its potential impact on decision-making.

MATERIALS AND METHODS

The retrospective study included 284 allo-HCT recipients. Recurrent BSI was defined as a new BSI episode occurring in a period of more than 72 hours after antibiotic withdrawal.

RESULTS

Overall, 104 patients (36.6%) developed at least one BSI, and 23 of them (22.1%) experienced recurrent BSI episodes (n = 30). Median time to recurrent BSI was 41 days (range 5-526 days). Recurrent BSI was associated with second allo-HCT (p < 0.0001), primary (p = 0.021), and secondary graft failure (p = 0.024). Carbapenem-resistant gram-negative bacteria were more common during recurrent BSI episodes (23.7% vs. 6.0%; p = 0.003). In only 17.5% patients experiencing recurrent BSI episode and in only 3.9% of patients with at least one BSI episode phenotypically identical recurring pathogen was isolated.

CONCLUSIONS

In view of low rate of recurrent BSI due to identical pathogen, empirical antimicrobial therapy should not be based on data on previous BSI episodes.

摘要

背景

尽管定植是导致血流感染(BSI)的既定危险因素,但在治疗发热性中性粒细胞减少症时,也应考虑先前感染耐药菌。本研究旨在分析异基因造血细胞移植(allo-HCT)受者复发性 BSI 的发生率和病因,以确定其对决策的潜在影响。

材料和方法

这项回顾性研究纳入了 284 例 allo-HCT 受者。复发性 BSI 定义为抗生素停药后超过 72 小时发生的新 BSI 发作。

结果

共有 104 例患者(36.6%)发生至少一次 BSI,其中 23 例(22.1%)发生复发性 BSI 发作(n=30)。复发性 BSI 的中位时间为 41 天(范围 5-526 天)。复发性 BSI 与二次 allo-HCT(p<0.0001)、原发性(p=0.021)和继发性移植物失败(p=0.024)相关。复发性 BSI 期间更常出现碳青霉烯类耐药革兰氏阴性菌(23.7%比 6.0%;p=0.003)。在经历复发性 BSI 发作的患者中,仅有 17.5%和在至少发生一次 BSI 发作的患者中,仅有 3.9%分离出表型相同的复发病原体。

结论

鉴于相同病原体引起的复发性 BSI 发生率较低,经验性抗菌治疗不应基于先前 BSI 发作的数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验